Other Stories

Celltrion's COVID-19 treatment gets conditional approval for medium and high-risk patients Updated: 2021-01-28 10:15:34 KST

Another footstep toward treating the coronavirus.
A treatment candidate from South Korean bio firm Celltrion was on Wednesday approved by the country's Ministry of Food and Drug Safety.
The Central Pharmacist Review Board, composed of 18 outside experts and 6 from Korea's drug ministry, evaluated its effectiveness and safety.
Conditional approval was granted for use on patients deemed to be medium or high risk but results from a third clinical trial need to be submitted.

"In contrast to the opinion of the last verification advisory group, the committee say that it's hard to recommend this treatment for mild cases and it should be used for a limited number of patients. Therefore, it's advised that this drug should be administered only to middle and high-risk patients."

Anyone receiving the treatment needs to be aged 18 or over and meet three other requirements.
First, a patient's oxygen saturation while indoors should not exceed 94 percent.
Second, patients should not need breathing assistance.
Lastly, the drug can only be given to those who have had symptoms for seven days minimum.
Jang Tae-hyun, Arirang News.
KOGL : Korea Open Government License
본 저작물 중 본문에 해당하는 뉴스 스크립트(텍스트)는 공공누리 제1유형-출처표시 조건에 따라 이용할 수 있습니다.